Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab sequential concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2100051160Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Started Nov 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100051160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051160.